“Chronic Refractory Cough Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Refractory Cough Market.

The Chronic Refractory Cough Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Refractory Cough Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Chronic Refractory Cough treatment therapies with a considerable amount of success over the years. 

• Chronic Refractory Cough companies working in the treatment market are Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing therapies for the Chronic Refractory Cough treatment 

• Emerging Chronic Refractory Cough therapies in the different phases of clinical trials are- NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others are expected to have a significant impact on the Chronic Refractory Cough market in the coming years.

• In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced the start of its Phase 2b CORAL clinical trial. The trial will evaluate three doses of Haduvio™ (oral nalbuphine ER) against a placebo in around 160 patients with idiopathic pulmonary fibrosis (IPF) who have chronic cough. This Phase 2b trial follows the successful results of the Phase 2a CANAL trial, which showed a significant 75.1% reduction in daytime cough frequency, a 52.5% improvement over placebo (p<0.0001). Haduvio is being developed for chronic cough in IPF, refractory chronic cough (RCC), and prurigo nodularis.

• In June 2023, Bellus Health Inc. and GSK plc declared Bellus has been fully acquired by GSK. Camlipixant, a potentially best-in-class and highly selective P2X3 antagonist that is presently in phase III development for the first-line treatment of adult patients with refractory chronic cough, is part of the Bellus purchase.

• In January 2023, A Phase III, 24-week, randomized, double-blind, placebo-controlled, parallel-arm effectiveness and safety trial was started by Bellus Health Inc. with an open-label extension of BLU-5937 for adult participants with refractory chronic cough, including chronic cough that is not explained. The experiment is expected to conclude with 675 participants by July 2025.  

Chronic Refractory Cough Overview

A cough that lasts longer than eight weeks is referred to as chronic, and many individuals with chronic refractory cough have coughs that last considerably longer. Furthermore, the illness is known as chronic refractory cough when the reason of the persistent cough cannot be found or the cough continues even after receiving the best care possible for any related conditions.

Get a Free Sample PDF Report to know more about Chronic Refractory Cough Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight

Emerging Chronic Refractory Cough Drugs Under Different Phases of Clinical Development Include:

• NOC-100: Nocion Therapeutics

• GDC-6599: Genentech, Inc.

• Haduvio: Trevi Therapeutics

• HRS-2261: Guangdong Hengrui Pharmaceutical Co., Ltd

• BLU-5937: Bellus Health Inc

• MK-7264 (gefapixant): Merck & Co/Kyorin Pharmaceuticals

• Orvepitant Maleate: NeRRe Therapeutics

• Camlipixant (BLU-5937): Bellus Health/GSK

• AX-8: Axalbion

• ADX-629: Aldeyra Therapeutics

• GDC-6599: Genentech, Inc.

Route of Administration

Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Chronic Refractory Cough Pipeline Therapeutics Assessment

• Chronic Refractory Cough Assessment by Product Type

• Chronic Refractory Cough By Stage and Product Type

• Chronic Refractory Cough Assessment by Route of Administration

• Chronic Refractory Cough By Stage and Route of Administration

• Chronic Refractory Cough Assessment by Molecule Type

• Chronic Refractory Cough by Stage and Molecule Type

DelveInsight’s Chronic Refractory Cough Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Refractory Cough product details are provided in the report. Download the Chronic Refractory Cough pipeline report to learn more about the emerging Chronic Refractory Cough therapies

Some of the key companies in the Chronic Refractory Cough Therapeutics Market include:

Key companies developing therapies for Chronic Refractory Cough are – Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics and others.

Chronic Refractory Cough Pipeline Analysis:

The Chronic Refractory Cough pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.

• Chronic Refractory Cough key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Refractory Cough drugs and therapies

Chronic Refractory Cough Pipeline Market Drivers

• Increasing Prevalence of cough, growing demand for treatment for Chronic Refractory Cough are some of the important factors that are fueling the Chronic Refractory Cough Market.

Chronic Refractory Cough Pipeline Market Barriers

• However, lack of awareness, lack of availability of specific biomarkers that are useful for accurate and timely diagnosis and other factors are creating obstacles in the Chronic Refractory Cough Market growth.

Scope of Chronic Refractory Cough Pipeline Drug Insight    

• Coverage: Global

• Key Chronic Refractory Cough Companies: Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others

• Key Chronic Refractory Cough Therapies: NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others

• Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies

• Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers 

Request for Sample PDF Report for Chronic Refractory Cough Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Refractory Cough Report Introduction

2. Chronic Refractory Cough Executive Summary

3. Chronic Refractory Cough Overview

4. Chronic Refractory Cough- Analytical Perspective In-depth Commercial Assessment

5. Chronic Refractory Cough Pipeline Therapeutics

6. Chronic Refractory Cough Late Stage Products (Phase II/III)

7. Chronic Refractory Cough Mid Stage Products (Phase II)

8. Chronic Refractory Cough Early Stage Products (Phase I)

9. Chronic Refractory Cough Preclinical Stage Products

10. Chronic Refractory Cough Therapeutics Assessment

11. Chronic Refractory Cough Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Refractory Cough Key Companies

14. Chronic Refractory Cough Key Products

15. Chronic Refractory Cough Unmet Needs

16 . Chronic Refractory Cough Market Drivers and Barriers

17. Chronic Refractory Cough Future Perspectives and Conclusion

18. Chronic Refractory Cough Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services